Dermatol. praxi. 2022;16(4):190-194 | DOI: 10.36290/der.2022.038

The News in a Treatment of Severe Forms of Acne

MUDr. Zuzana Nevoralová, Ph.D.
Kožní oddělení nemocnice, Jihlava

In the first part of the article, a term severe acne is identified. Acne fulminans and acne fulminans sine fulminans are described in detail. There exist a recommendation for a treatment of severe forms od acne from 2016, peroral isotretinoin is a primary medicine in a treatment. This fact is valid till now but some recommendations for a treatment with this medicine have changed. There are especially a daily recommended dose (lower doses are prefered now), a length of a treatment (not a total cumulative dose but a length of a treatment after patient´s healing is important ) and a possibility of prevention of isotretinoin induced acne fulminans. Later, data about acne treatment with peroral antihistamines are given. It was found out that antihistamines interfere with acne progression and could become a new medicine in acne treatment, especially in a combinatiom with peroral isotretinoin. Acne treatment has always to be completed with an application of a suitable dermocosmetics. After healing of acne a maintenance therapy is necessary.

Keywords: acne, fulminans, isotretinoin, corticoids, antihistamines, dermocosmetics.

Accepted: November 29, 2022; Published: December 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevoralová Z. The News in a Treatment of Severe Forms of Acne. Dermatol. praxi. 2022;16(4):190-194. doi: 10.36290/der.2022.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dréno B. What is new in the pathophyziology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31(Suppl 5):8-12. Go to original source... Go to PubMed...
    2. Plewig G, Melnik B, Chen W. Acne Classification and Disease Burden. In: Plewig G, Melnik B, Chen W. Plewig and Kligman´s Acne and Rosacea. ISBN 978-3-319-49273-5 4rd ed. Springer Natur Switzerland AG 2019:217-218. Go to original source...
    3. Dreno B, et al. Development and evaluation of a Global Severity Acne Scale suitable for France and Europe, J Eur Acad Dermatol Venereol. 2011;25:23-48. Go to original source... Go to PubMed...
    4. Plewig G, Melnik B, Chen W. Acne fulminans. In: Plewig G, Melnik B, Chen, W. Plewig and Kligman´s Acne and Rosacea. ISBN 978-3-319-49273-5 4rd ed. Springer Natur Switzerland AG. 2019:412-416.
    5. Greywal T, Zaenglein AL, Baldwin HE, et al. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol. 2017;77(1):109-117. Go to original source... Go to PubMed...
    6. Nevoralová Z. Léčba akné. In: Rulcová J, Benáková N. Obličejové dermatózy, 2. přepracované a doplněné vydání. Mladá fronta 2018, ISBN 978-80-2014-4891-0:27-49.
    7. Gollnick HPM, et al. A consensus-based practical and daily guide for the treatment of acne patients. J EurAcad Dermatol Venereol 2016 epub. DOI: 0.1111/jdv.13675. Go to original source... Go to PubMed...
    8. Nevoralová Z. Izotretinoin v praxi. Mladá fronta 2012, ISBN 978-80-204-2695-6.
    9. Nast A, Dréno B, Bettoli V, et al. European Evidence-based (S3) Guidelines for the Treatment of Acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 1):1-29. Go to original source... Go to PubMed...
    10. Kemény L. Isotretinoin: An update on the optimal dose. Lecture D2T02.1C, 31st EADV Congress Milano, September 7-10, 2022.
    11. See, JoAnn. Low doses versus standard doses of isotretinoin in moderate-to-severe acne: Low doses. Lecture D3T09.1B 31st, EADV Congress Milano, September 7-10, 2022.
    12. Zoubolis CH C. Low doses verus standard doses of isotretinoin in moderate-to-severe acne: High doses. Lecture D3T09.1C, 31st EADV Congress Milano, September 7-10, 2022.
    13. Thiboutot TM, Dréno B, Abanmi B, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2),Suppl 1:S1-S23. Go to original source... Go to PubMed...
    14. Schaller M. How to manage severe acne with isotretinoin. Acne symposium. On-line EADV Spring Symposium, May 6-7, 2021.
    15. Nevoralová Z. Novinky v léčbě perorálním izotretinoinem, Dermatologie pro praxi. 2017;11(1):22-26. Go to original source...
    16. Pelle E, McCarthy J, Seltmann H, et al. Identification of histamine receptors and reduction of squalene levels by an antihistamine in sebocytes. J Invest Dermatol 2007;128: 1280-1285. Go to original source... Go to PubMed...
    17. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-762. Go to original source... Go to PubMed...
    18. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000;50:345-352. Go to original source... Go to PubMed...
    19. Affrime M, Gupta S, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002;41(Suppl 1):13-19. Go to original source... Go to PubMed...
    20. Genovese A, Patella V, De Crescenzo G, et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27:559-567. Go to original source... Go to PubMed...
    21. Lippert U, Kruger-Krasagakes S, Moller A, et al. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272-276. Go to original source... Go to PubMed...
    22. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31:1369-1377. Go to original source... Go to PubMed...
    23. Reich A, Trybucka K, Tracinska A, et al. Acne itch: do acne patients suffer from itching? Acta Derm Venereol 2008;88:38-42. Go to original source... Go to PubMed...
    24. Lee HE, Chang IK, Lee Y, et al. Antihistamine as an adjuvant treatment of isotretinoin in acne, J Eur Acad Dermatol Venereol 2014;28(12):1654-1660. Go to original source... Go to PubMed...
    25. Thuong, Nguyen Van, Lan, Duong Thi, Hao, Nguyen Trong et al: Efficacy of Oral Isotretinoin in Combination with Desloratadine in the Treatment of Common Vulgaris Acne in Vietnamese Patients, Maced J Med Sci 2019;7(2):217-220. Go to original source... Go to PubMed...
    26. Garbuzenko E, Nagler A, Pickholtz D, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002;32:237-246. Go to original source... Go to PubMed...
    27. Yukselen V, Karaoglu AO, Ozutemiz O, et al. Ketotifen ameliorates development of fibrosis in alkali burns of the esophagus. Pediatr Surg Int 2004;20:429-433. Go to original source... Go to PubMed...
    28. Yosef A, Dawoud NM, Gharib K. Preliminary evaluation of the clinical efficacy of antihistamines as an adjuvant treatment to isotretinoin for acne vulgaris. Journal of the Egyptian Women's Dermatologic Society. 2017;14(1):49-55. Go to original source...
    29. Pandey M, Agrawal W. Efficacy of Isotretinoin and Antihistamine versus Isotretinoin Alone in the Treatment of Moderate to Severe Acne: A Randomised Control. Kathmandu Univ Med J 2019;65(1):14-19. Go to original source... Go to PubMed...
    30. Yavari, V: Antihistamines may be used as an "adjuvant" in treatment of all kinds of acne. Med Hypotheses 2006; 66:447-448. Go to original source... Go to PubMed...
    31. Wang L. Antihistamine: A Useful Medication with Minimal Adverse Drug Reactions to Improve Acne Symptoms and Reduce Sebum Production" (2015). School of Physician Assistant Studies. Paper 508.
    32. Aravilskaia E, Dreno B. The role of topical dermocosmetics in acne vulgaris. J Am Acad Dermatol 2016;30:926-935. Go to original source... Go to PubMed...
    33. Nevoralová Z. Udržovací léčba akné. Dermatol. Praxi. 2016;10(1):10-15. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.